Stem cell therapeutics developer Athersys’ (NASDAQ:ATHX) phase 2 clinical study investigating the treatment of inflammatory bowel disease with partner Pfizer (NYSE:PFE) is expected to complete patient enrollment by the end of 2012. Top-line results of the inflammatory bowel disease trial are likely to be available in early 2013, Athersys CEO Gil Van Bokkelen said in […]
Takeda Pharmaceuticals is a strategic investor in regenerative medicine company Juventas Therapeutics’ upcoming series B round of funding. Juventas’ CEO Rahul Aras discussed the investment during a panel at a meeting of the Ohio Venture Association on Friday. “If you think venture capital due diligence is difficult …” Aras joked, “I think [Takeda] called my […]
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The U.S. Food and Drug Administration has cited a plastic surgery practice over several violations tied to its use of adult stem cells for breast augmentation and other procedures to manufacturing violations. In a warning letter to Dr. Thomas E. Young, the owner and medical director of Young Medical Spa, the FDA’s Center for Biologics […]
A startup has set out to create a biobank of stem cell-rich tissues collected during surgery with the idea that customers can use their own stored biomaterials for use in future bone graft procedures and stem cell therapies. Cleveland-based CellBank Technologies is modeling parts of its business on the cord blood bank industry, but instead […]
A cell culture startup that attracted attention last year for providing the scaffold used in the world’s second-ever artificial trachea implant has landed a $500,000 investment. Columbus, Ohio-based Nanofiber Solutions has received a $500,000 convertible loan from state-backed business development group TechColumbus, Columbus Business First reported. The company’s cell culture products use polymer nanofibers to […]
Results of a preclinical study suggest that stem cell technology from Athersys (NASDAQ:ATHX) could offer a treatment for patients suffering from a rare disorder called “Hurler’s syndrome.” Hurler’s syndrome is a metabolic disorder in which patients produce too little of an enzyme that helps the body break down a complex type of sugar molecule found […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
There are a series of medical megatrends outlined in my book The Future of Medicine – Megatrends in Healthcare that will profoundly affect health care in the coming five to fifteen years and beyond. Some are due to the explosion of basic understandings of cellular and molecular biology. Others are related to advances in engineering […]
Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease. Graft-versus-host disease (GvHD) often occurs after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient’s body. The condition is often associated with […]
A biopharmaceutical company developing cancer therapies that zero in on cancer stem cells to treat brain cancer and acute myeloid leukemia is seeking to raise $50 million in an initial public offering. Cancer stem cells are viewed as highly malignant “seeds” of tumors, according to the company’s website. Although they account for 5 percent or […]
Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most recent quarterly earnings call. Van Bokkelen said Cleveland-based Athersys’ MultiStem stem cell therapy for ischemic stroke “could easily be one of the biggest blockbusters that […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As the basketball frenzy that accompanies March Madness draws to the fever pitch of the Final Four, it brings to mind that basketball is a high contact sport. A quick peek at the NBA injured list reveals a catalog of breaks and tears that affect tendons, ligaments and bones. The pressure to improve performance and […]
The head of a stem cell company has responded to a warning letter issued by the U.S. Food and Drug Administration that cites several violations at the company that derives stem cells from adipose tissue or body fat. Dr. Steven Victor of IntelliCell BioSciences said it would be moving to a new facility next month […]
A warning letter issued by the U.S. Food and Drug Administration has cited numerous violations by a stem cell company and claimed it did not have an appropriate license to produce stem cells. IntelliCell BioSciences in New York derives stem cells from adipose tissue, or fat cells, for treatments ranging from lower back pain to […]
Regenerative medicine startup Juventas Therapeutics is planning to begin enrollment in a phase 2 heart failure clinical trial next quarter. The Cleveland-based company’s technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels and prevent ongoing cell death at the site of a patient’s injury. During the trial, Juventas […]
Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to purchase common shares at a price of $2.07. The warrants are exercisable for five years, according to a […]